Module 1: Foundational Principles & General
Pharmacology
50 High-Yield MSN/NP-Level Prac ce Ques ons
Scope note: These ques ons are original and based on generalized pharmacology principles
rather than any specific textbook or commercial ques on bank. Prescrip on-law requirements
vary by jurisdic on and controlled-substance schedule; where relevant, the ques ons use
broadly applicable elements of a complete prescrip on.
Ques on 1 — Passive Diffusion and Drug Absorp on
A 46-year-old pa ent with stable hypertension is prescribed an oral medica on that is highly
lipid-soluble, nonionized at physiologic pH, and has a rela vely low molecular weight. The
pa ent asks the NP how this medica on is most likely to cross the gastrointes nal epithelial
membrane.
Which mechanism best explains the drug's absorp on?
A. Passive transcellular diffusion through the lipid bilayer
B. ATP-dependent transport through an intes nal efflux pump
C. Paracellular movement through ght junc ons between enterocytes
D. Receptor-mediated endocytosis into intes nal epithelial cells
Clinical Ra onale
Correct answer: A. Passive transcellular diffusion through the lipid bilayer
A drug that is lipid-soluble, nonionized, and rela vely small readily traverses biological
membranes by passive transcellular diffusion. This process follows a concentra on gradient and
does not require cellular energy or a specific transporter. The degree of ioniza on is par cularly
important because the nonionized frac on is generally more membrane-permeable.
,Why B is incorrect: Ac ve transport requires a carrier and frequently energy. Efflux transporters
such as P-glycoprotein generally move selected drugs out of enterocytes rather than
represen ng the primary mechanism for a highly lipophilic drug crossing into systemic
circula on.
Why C is incorrect: Paracellular passage is limited by ght junc ons and is more relevant to very
small hydrophilic molecules. It is not the dominant mechanism for a typical lipophilic
medica on.
Why D is incorrect: Receptor-mediated endocytosis is not the usual mechanism for absorp on
of conven onal small-molecule oral drugs.
Ques on 2 — Gastric pH and Drug Ioniza on
A pa ent taking an oral weakly acidic medica on begins chronic proton-pump inhibitor therapy.
The pa ent subsequently experiences reduced systemic exposure to the medica on.
Which pharmacokine c principle best explains the poten al change?
A. Increased gastric pH can alter the drug's ioniza on and dissolu on characteris cs
B. Increased gastric pH universally increases absorp on of weak acids
C. Proton-pump inhibitors directly inhibit renal filtra on of weak acids
D. Gastric alkaliniza on accelerates hepa c glucuronida on of all medica ons
Clinical Ra onale
Correct answer: A. Increased gastric pH can alter the drug's ioniza on and dissolu on
characteris cs
Gastric pH can influence the ioniza on, dissolu on, and subsequent absorp on of orally
administered medica ons. The rela onship is drug-specific; pH changes do not uniformly
increase or decrease absorp on.
,Why B is incorrect: Weak acids tend to become more ionized as pH rises, but absorp on
depends on mul ple factors, including formula on, dissolu on, surface area, intes nal transit,
and whether the gastrointes nal tract rather than the stomach is the principal absorp on site.
Why C is incorrect: Proton-pump inhibitors do not directly inhibit renal filtra on of weak acids.
Why D is incorrect: Gastric alkaliniza on does not universally accelerate hepa c
glucuronida on. Hepa c conjuga on is an enzyma c metabolic process occurring primarily
a er systemic absorp on.
Ques on 3 — First-Pass Metabolism
A 58-year-old pa ent receives two formula ons of the same medica on. The oral formula on
produces substan ally lower systemic drug concentra ons than an equivalent dose
administered intravenously.
Which pharmacokine c phenomenon most directly explains this difference?
A. Presystemic gastrointes nal and hepa c metabolism
B. Increased renal tubular secre on a er intravenous administra on
C. Increased plasma protein binding following oral administra on
D. Delayed drug distribu on into peripheral ssues a er intravenous administra on
Clinical Ra onale
Correct answer: A. Presystemic gastrointes nal and hepa c metabolism
Orally administered medica ons enter the portal circula on and may undergo substan al first-
pass metabolism in the intes nal wall and liver before reaching systemic circula on.
Consequently, oral bioavailability may be substan ally lower than intravenous bioavailability.
Why B is incorrect: Renal secre on occurs a er systemic circula on is reached and does not
explain the ini al reduc on in oral bioavailability.
, Why C is incorrect: Protein binding can influence free drug concentra on and distribu on but
does not adequately explain the classic oral-versus-IV bioavailability difference.
Why D is incorrect: Distribu on occurs a er systemic entry and therefore cannot account for
reduced ini al bioavailability from oral administra on.
Ques on 4 — Protein Binding
A 72-year-old pa ent with severe hypoalbuminemia begins therapy with a medica on that is
normally 98% albumin-bound. Shortly a erward, the pa ent develops manifesta ons consistent
with excessive pharmacologic ac vity despite receiving the prescribed dose.
What is the most likely mechanism?
A. Increased unbound drug frac on capable of interac ng with pharmacologic targets
B. Decreased concentra on of pharmacologically ac ve free drug
C. Complete inhibi on of renal filtra on of the medica on
D. Conversion of the medica on into an inac ve metabolite by albumin
Clinical Ra onale
Correct answer: A. Increased unbound drug frac on capable of interac ng with
pharmacologic targets
Only the unbound frac on of most protein-bound medica ons readily crosses membranes,
distributes into ssues, undergoes metabolism, and interacts with receptors. Severe
hypoalbuminemia can increase the free frac on of highly albumin-bound drugs. For drugs with
a narrow therapeu c index, this can have major clinical consequences.
Why B is incorrect: Hypoalbuminemia generally increases—not decreases—the unbound
frac on.
Why C is incorrect: Albumin concentra on does not directly determine whether a drug
undergoes glomerular filtra on.
Pharmacology
50 High-Yield MSN/NP-Level Prac ce Ques ons
Scope note: These ques ons are original and based on generalized pharmacology principles
rather than any specific textbook or commercial ques on bank. Prescrip on-law requirements
vary by jurisdic on and controlled-substance schedule; where relevant, the ques ons use
broadly applicable elements of a complete prescrip on.
Ques on 1 — Passive Diffusion and Drug Absorp on
A 46-year-old pa ent with stable hypertension is prescribed an oral medica on that is highly
lipid-soluble, nonionized at physiologic pH, and has a rela vely low molecular weight. The
pa ent asks the NP how this medica on is most likely to cross the gastrointes nal epithelial
membrane.
Which mechanism best explains the drug's absorp on?
A. Passive transcellular diffusion through the lipid bilayer
B. ATP-dependent transport through an intes nal efflux pump
C. Paracellular movement through ght junc ons between enterocytes
D. Receptor-mediated endocytosis into intes nal epithelial cells
Clinical Ra onale
Correct answer: A. Passive transcellular diffusion through the lipid bilayer
A drug that is lipid-soluble, nonionized, and rela vely small readily traverses biological
membranes by passive transcellular diffusion. This process follows a concentra on gradient and
does not require cellular energy or a specific transporter. The degree of ioniza on is par cularly
important because the nonionized frac on is generally more membrane-permeable.
,Why B is incorrect: Ac ve transport requires a carrier and frequently energy. Efflux transporters
such as P-glycoprotein generally move selected drugs out of enterocytes rather than
represen ng the primary mechanism for a highly lipophilic drug crossing into systemic
circula on.
Why C is incorrect: Paracellular passage is limited by ght junc ons and is more relevant to very
small hydrophilic molecules. It is not the dominant mechanism for a typical lipophilic
medica on.
Why D is incorrect: Receptor-mediated endocytosis is not the usual mechanism for absorp on
of conven onal small-molecule oral drugs.
Ques on 2 — Gastric pH and Drug Ioniza on
A pa ent taking an oral weakly acidic medica on begins chronic proton-pump inhibitor therapy.
The pa ent subsequently experiences reduced systemic exposure to the medica on.
Which pharmacokine c principle best explains the poten al change?
A. Increased gastric pH can alter the drug's ioniza on and dissolu on characteris cs
B. Increased gastric pH universally increases absorp on of weak acids
C. Proton-pump inhibitors directly inhibit renal filtra on of weak acids
D. Gastric alkaliniza on accelerates hepa c glucuronida on of all medica ons
Clinical Ra onale
Correct answer: A. Increased gastric pH can alter the drug's ioniza on and dissolu on
characteris cs
Gastric pH can influence the ioniza on, dissolu on, and subsequent absorp on of orally
administered medica ons. The rela onship is drug-specific; pH changes do not uniformly
increase or decrease absorp on.
,Why B is incorrect: Weak acids tend to become more ionized as pH rises, but absorp on
depends on mul ple factors, including formula on, dissolu on, surface area, intes nal transit,
and whether the gastrointes nal tract rather than the stomach is the principal absorp on site.
Why C is incorrect: Proton-pump inhibitors do not directly inhibit renal filtra on of weak acids.
Why D is incorrect: Gastric alkaliniza on does not universally accelerate hepa c
glucuronida on. Hepa c conjuga on is an enzyma c metabolic process occurring primarily
a er systemic absorp on.
Ques on 3 — First-Pass Metabolism
A 58-year-old pa ent receives two formula ons of the same medica on. The oral formula on
produces substan ally lower systemic drug concentra ons than an equivalent dose
administered intravenously.
Which pharmacokine c phenomenon most directly explains this difference?
A. Presystemic gastrointes nal and hepa c metabolism
B. Increased renal tubular secre on a er intravenous administra on
C. Increased plasma protein binding following oral administra on
D. Delayed drug distribu on into peripheral ssues a er intravenous administra on
Clinical Ra onale
Correct answer: A. Presystemic gastrointes nal and hepa c metabolism
Orally administered medica ons enter the portal circula on and may undergo substan al first-
pass metabolism in the intes nal wall and liver before reaching systemic circula on.
Consequently, oral bioavailability may be substan ally lower than intravenous bioavailability.
Why B is incorrect: Renal secre on occurs a er systemic circula on is reached and does not
explain the ini al reduc on in oral bioavailability.
, Why C is incorrect: Protein binding can influence free drug concentra on and distribu on but
does not adequately explain the classic oral-versus-IV bioavailability difference.
Why D is incorrect: Distribu on occurs a er systemic entry and therefore cannot account for
reduced ini al bioavailability from oral administra on.
Ques on 4 — Protein Binding
A 72-year-old pa ent with severe hypoalbuminemia begins therapy with a medica on that is
normally 98% albumin-bound. Shortly a erward, the pa ent develops manifesta ons consistent
with excessive pharmacologic ac vity despite receiving the prescribed dose.
What is the most likely mechanism?
A. Increased unbound drug frac on capable of interac ng with pharmacologic targets
B. Decreased concentra on of pharmacologically ac ve free drug
C. Complete inhibi on of renal filtra on of the medica on
D. Conversion of the medica on into an inac ve metabolite by albumin
Clinical Ra onale
Correct answer: A. Increased unbound drug frac on capable of interac ng with
pharmacologic targets
Only the unbound frac on of most protein-bound medica ons readily crosses membranes,
distributes into ssues, undergoes metabolism, and interacts with receptors. Severe
hypoalbuminemia can increase the free frac on of highly albumin-bound drugs. For drugs with
a narrow therapeu c index, this can have major clinical consequences.
Why B is incorrect: Hypoalbuminemia generally increases—not decreases—the unbound
frac on.
Why C is incorrect: Albumin concentra on does not directly determine whether a drug
undergoes glomerular filtra on.
